Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Type 2 Diabetes Market?

The market size for type 2 diabetes has seen significant expansion in the recent past. It will increase from a size of $48.14 billion in 2024 to $51.96 billion in 2025, with a compound annual growth rate (CAGR) of 7.9%. The historic period’s growth can be ascribed to modifications in lifestyle and diet, increasing elderly population, advancements in pharmaceuticals, and public health initiatives.

What Growth Rate Is Forecasted for the Type 2 Diabetes Market by 2029?

The market for type 2 diabetes is anticipated to undergo robust expansion in the coming years, escalating to a value of $72.22 billion in 2029 with a CAGR of 8.6%. The progression during the predicted period is ascribed to the worldwide diabetes outbreak, individualized treatment options, advancements in technology, and alterations in healthcare policies. Key trends to lookout for during the forecast period encompass digital health and telemedicine, prevention coupled with early intervention strategies, artificial intelligence (AI) and machine learning (ML), and metabolic surgery.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13050&type=smp

Which Key Companies Are Shaping the Future of the Type 2 Diabetes Market?

Major companies operating in the type 2 diabetes market are F. Hoffmann-La Roche AG, Merck and Co. Inc., Novartis AG, AstraZeneca PLC, Abbott Laboratories, Sanofi SA, Medtronic PLC, Takeda Pharmaceutical Company, GlaxoSmithKline plc., Eli Lilly and Company, Novo Nordisk A/S, Johnson And Johnson Private Limited, Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Dexcom Inc., Amgen Inc., Insulet Corporation, Ascensia Diabetes Care, Byram Healthcare, Beta Bionics, Onduo LLC, DarioHealth, One Drop, Bigfoot Biomedical Inc., Digbi Health, MySugr GmbH, Senseonics Holdings Inc., Provention Bio Inc., Vida Health Inc., Diathrive Health.

Which Factors Are Driving Demand in the Type 2 Diabetes Industry?

The expansion of the type 2 diabetes market is anticipated to be fueled by the growing prevalence of obesity and heart disease. Obesity is characterized as a health condition resulting from the accumulation of an unhealthy level of excess body fat, while heart disease encompasses different disorders that impact the heart and blood vessels. Being overweight escalates the risk of insulin resistance that leads to elevated blood sugar levels and eventually, type 2 diabetes. Moreover, high blood sugar is detrimental to blood vessels and nerves regulating the heart and blood vessels, resulting in heart disease. For example, in March 2024, the World Health Organization (WHO), an intergovernmental organization based in Switzerland, indicated that one in every eight people globally was battling obesity. This accounted for 2.5 billion adults (18 years and older) who were overweight, with 890 million suffering from obesity. Among these adults, 43% were noted to be overweight, and 16% were categorized as obese. The number of children less than five years of age and overweight was stated to be 37 million. Therefore, the escalating rates of obesity and heart disease are contributing to the development of the type 2 diabetes market. The next driver stimulating the expansion of the type 2 diabetes market is the growing geriatric population. This term is used to denote individuals aged 65 years and above. The elder populace is susceptible to a host of diseases due to lowered immunity and advancing age. The risk of problems associated with type 2 diabetes such as hypoglycemia (diminished blood sugar), renal failure, and heart disease increases with age, affecting both acute and chronic microvascular and cardiovascular complications. For instance, the World Health Organization stated in July 2023 that by 2030, one in every six people globally would be aged 60 years or older. The count of people aged 60 and above worldwide will witness a twofold increase (reaching 2.1 billion) by 2050. The period from 2020 to 2050 will see the emergence of an additional 426 million people who are 80 years or older compared to the present number. Therefore, the growing geriatric population is stimulating the type 2 diabetes market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13050&type=smp

How Is the Type 2 Diabetes Market Segmented by Several Divisions?

The type 2 diabetes market covered in this report is segmented –

1) By Drug Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Sulfonylureas And Other Insulin Secretagogues, Biguanides, SodiumGlucose Cotransporter 2 Inhibitors, Other Drug Classes

2) By Application: Glycemic Control, Cardiovascular Safety, Hypoglycemia Avoidance, Other Applications

3) By End-User: Children, Adults

Subsegments:

1) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin

2) By Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Liraglutide, Semaglutide, Dulaglutide, Exenatide

3) By Thiazolidinediones: Pioglitazone, Rosiglitazone

4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol

5) By Sulfonylureas And Other Insulin Secretagogues: Glimepiride, Glipizide, Glyburide

6) By Biguanides: Metformin

7) By Sodium-Glucose Cotransporter 2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

8) By Other Drug Classes: Amylin Analogues, Bile Acid Sequestrants, Dopamine Agonists

What are the Emerging Market Trends Driving the Growth of the Type 2 Diabetes Industry?

The type 2 diabetes market is marked by the introduction of innovative products by leading companies such as Mounjaro, with the motive of elevating safety and performance standards for those dealing with diabetes. These pioneer drugs, for example, Mounjaro, are designed to intensify the success rate, safety, or simplicity of managing diabetes, in comparison to previously available medicines. The current advancements in diabetes medications are centered around enhancing control over blood sugar, curbing potential side effects, and dealing with other associated health problems. One such instance is Eli Lilly and Co, a pharmaceutical company from the United States, who secured approval in May 2022 from the U.S. Food and Drug Administration, a government body, for Mounjaro’s (tripeptide) injection. This solution targets improved sugar level control in adults with type 2 diabetes along with dietary and physical activity adjustments. Tirzepatide emerges as a fresh, dual-action solution for type 2 diabetes. Administered as a once-weekly injection, it targets two hormones located in blood sugar regulation, specifically, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 functions to stimulate insulin production and reduce glucagon production whereas GIP aids in boosting insulin production. As a result, Tirzepatide holds immense promise as a new treatment avenue for individuals dealing with type 2 diabetes, including those who failed to respond positively to other available treatments.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/type-2-diabetes-global-market-report

Which Regions Are Driving Growth in the Type 2 Diabetes Market?

North America was the largest region in the type 2 diabetes market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in type 2 diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13050

This Report Delivers Insight On:

1. How big is the type 2 diabetes market, and how is it changing globally?

2. Who are the major companies in the type 2 diabetes market, and how are they performing?

3. What are the key opportunities and risks in the type 2 diabetes market right now?

4. Which products or customer segments are growing the most in the type 2 diabetes market?

5. What factors are helping or slowing down the growth of the type 2 diabetes market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model